摘要
目的 研究维生素D在慢性丙型肝炎(CHC)患者接受聚乙二醇干扰素α-2b(Peg-IFNα-2b)联合利巴韦林(RBV)抗病毒治疗中的作用。方法本研究为前瞻性随机对照试验,共纳入52例CHC初治患者,随机分为维生素D补充治疗组(A组)、对照组(B组),A组26例患者口服补充维生素D 800 IU/d至Peg-IFNα-2b/RBV抗病毒治疗结束,B组26例患者仅接受Peg-IFNα-2b/RBV抗病毒治疗。检测患者治疗前、治疗4周、12周、24周、48周时HCV RNA水平等指标。结果治疗24周、48周时维生素D补充治疗组病毒学应答率均显著高于对照组(95.8%vs 69.6%,95.8%vs 73.9%,P均<0.05),但两组早期病毒学应答(EVR)无统计学差异(91.7%vs 69.6%,P>0.05)。两组不良事件发生率并无差异(73.1%vs 80.8%,P>0.05)。结论补充维生素D能提高CHC患者Peg-IFNα-2b/RBV抗病毒疗效。
Objective To study the effect of vitamin D on the antiviral therapy of pegylated interferon α-2b（Peg-IFNα- 2b） combined with ribavirin（RBV） in the patients with chronic hepatitis C（CHC）. Methods The study was a prospective, randomized and controlled trial. A total of 52 patients with CHC were enrolled in this study. They were randomly divided into vitamin D supplementation group （group A）, control group （group B）. Group A of 26 patients was orally given vita- min D 800 IU/d until the end of antiviral therapy of Peg-IFNα-2b/RBV, while group B of 26 patients was only given antiviral therapy of Peg-IFNα-2b/RBV. The levels of HCV RNA were measured before the treatment and 4 weeks, 12 weeks, 24 weeks and 48 weeks after the treatment. Results The virological response rate in the vitamin D supplementa- tion group at 24 weeks and 48 weeks was significantly higher than that in the control group （95.8% vs 69.6%, 95.8% vs 73.9%, P all 〈0.05）. However, there was no significant difference in early virological response （EVR） between the two groups（91.7% vs 69.6%, P〉0.05）. There was no difference in the incidence rate of adverse events between the two groups （73.1% vs 80.8%, P〉0.05）. Conclusion Vitamin D supplementation can improve the antiviral efficacy of Peg-IFNα-2b/ RBV in CHC patients.
作者
刘敏慧
陈海君
张德和
汤慧
LIU Minhui CHEN Haijun ZHANG Dehe TANG Hui(Department of Infection, Jinhua Central Hospital in Zhejiang Province, Jinhua 321000, China Institute of Viral Hepatitis, Chongqing Medical University, Chongqing 400016, China)
出处
《中国现代医生》
2017年第4期23-27,共5页
China Modern Doctor
基金
国家自然科学基金(81300258)
